
SCARD Pool report for 01-01-2003 to 31-12-2003

Participants	Doctors	13	
	Patients	113	
Specimens	New lesions	152	78.35%
	Previously biopsied lesions	42	21.65%
	Total lesions	194	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	63.70%
Percentage of Definitively excised lesions that were malignant	65.17%
Lesions tested to find one melanoma (NNT)	2.75
Percentage of lesions tested for NMSC which were NMSC	73.28%
Ratio of New BCCs : New Melanomas	7:1

Accuracy

Diagnostic sensitivity

Melanomas	75.00% of 8
All NMSC	94.12% of 85
BCCs	90.57% of 53
SCCs	71.88% of 32

Positive predictive value

Melanomas	54.55% of 11
All NMSC	86.02% of 93
BCCs	51.61% of 93
SCCs	69.70% of 33

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate


BCC	86.36% of 22
IEC/Bowens disease	100.00% of 1
SCC	83.33% of 12
Keratoacanthoma	0% of 0
Melanoma - in situ	100.00% of 5
Melanoma - invasive	0% of 0
Melanoma - invasive > 1mm	0% of 0
Other malignant	0% of 0

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	17	11.18%
BCC - Superficial	14	9.21%
BCC - Nodular/Solid	14	9.21%
BCC - Aggressive	8	5.26%
IEC/Bowens disease	14	9.21%
SCC	18	11.84%
Keratoacanthoma	0	0%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	0	0%
NMSC Metastasis	0	0%
Melanoma - in situ	5	3.29%
Melanoma - invasive	2	1.32%
Melanoma - invasive > 1mm	1	0.66%
Melanoma - metastasis	0	0%
MELTUMP	0	0%
Naevus - other	5	3.29%
Naevus - dysplastic/Clark	3	1.97%
Naevus - blue	1	0.66%
Naevus - Spitz/Reed	0	0%
Naevus - Compound	1	0.66%
Solar keratosis	13	8.55%
Solar lentigo	3	1.97%
Seborrhoeic keratosis	14	9.21%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	0	0%
Dermatofibroma	0	0%
Sebaceous gland hyperplasia	0	0%
Benign cyst	6	3.95%
Other benign	7	4.61%
Histology Pending	0	0%



© 2026 SCARD Systems Pty Ltd

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	12	92.31%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	0	0%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	1	7.69%
Other	0	0%

Biopsy used to exclude melanoma

Punch - sample	9	64.29%
Shave - sample	0	0%
Incisional	0	0%
Punch - removal	1	7.14%
Shave - removal	0	0%
Excisional	3	21.43%
Curettage	0	0%
Other	1	7.14%

Breakdown of definitive management procedures for malignant conditions

Ellipse	37	44.58%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	21	25.30%
Liquid N2 freeze/thaw	2	2.41%
PDT	0	0%
Imiquimod	3	3.61%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	20	24.10%
Other	0	0%

Breakdown of definitive management procedures for benign conditions

Ellipse	15	51.72%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Liquid N2 freeze/thaw	4	13.79%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	1	3.45%
Other	0	0%

© 2026 SCARD Systems Pty Ltd

Procedures (continued)


Percentage of procedures/closures that were complex

Complex Closures	0% of 21
Complex Closures (inc Curettage & Cautery)	0% of 30

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	0	0% of 5
Lip	0	0% of 0
Ear	0	0% of 6
Eyelid	0	0% of 0
Other face	0	0% of 29
Scalp	0	0% of 5
Neck	1	16.67% of 6
Shoulder	0	0% of 1
Chest	0	0% of 9
Abdomen	1	20.00% of 5
Genitalia	0	0% of 0
Back	1	4.17% of 24
Buttock	0	0% of 0
Arm	0	0% of 4
Forearm	3	16.67% of 18
Hand Dorsal	0	0% of 8
Hand Palmar	0	0% of 0
Finger Dorsal	0	0% of 2
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 0
Thigh	1	11.11% of 9
Leg	0	0% of 20
Foot Dorsal	0	0% of 0
Foot Plantar	0	0% of 0
Toe Dorsal	0	0% of 0
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd